Market Size of Prophylactic HIV Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 4.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Prophylactic HIV Drugs Market Analysis
The Prophylactic HIV Drugs Market is expected to register a CAGR of 4.10% during the forecast period.
The market is expected to grow owing to factors such as the high prevalence of HIV cases, increasing government initiatives, and increasing research and development activities. In addition, growing awareness of HIV prevention is also expected to drive the market growth over the forecast period. The high burden of new and existing HIV cases is expected to boost the market growth over the study period.
For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) factsheet 2023, in 2022, 51 thousand new HIV infections were reported compared to 48 thousand new cases in previous years. Similarly, as per the same source, the number of people living with HIV in Brazil was reported to be 990 thousand in 2022. This shows the significantly high burden of HIV, which is expected to increase the need for prophylactic HIV drugs to prevent spread and is likely to propel the market growth over the forecast period.
A large number of non-profit and government organizations are initiating various programs or studies to prevent HIV through various products, which is likely to propel the growth of the market. For instance, in April 2024, the CATALYST study of the United States Agency for International Development (USAID) expanded HIV prevention options for women and girls in Africa. This study provides complete information on and access to three biomedical HIV prevention methods, which include daily oral pre-exposure prophylaxis (PrEP) and newly-introduced injectable cabotegravir for PrEP (CAB PrEP) and others. Hence, government initiatives to provide awareness on the prevention of HIV are expected to drive market growth over the study period.
In addition, product developments, launches, and approval by regulatory authorities are expected to support market expansion over the forecast period. For instance, in October 2023, Gilead Sciences Inc. reported the phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study assesses the persistence of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who benefit from pre-exposure prophylaxis (PrEP). Thus, such efforts by market participants may result in the launch of advanced preventive therapy, which is expected to boost market growth over the forecast period.
However, lower penetration in an underdeveloped market and side effects of this drug, such as vomiting, nausea, tiredness, and diarrhea, are expected to restrain the market's growth over the forecast period.
Prophylactic HIV Drugs Industry Segmentation
As per the scope of the report, human immunodeficiency virus (HIV) is a chronic and life-threatening disease. The disease can be transferred from one person to another through blood-to-blood or sexual contact. HIV prophylactic drugs are the medication that is given to prevent HIV disease before it even occurs.
The prophylactic HIV drugs market is segmented by drug, dosage form, and geography. By drug, the market is segmented into tenofovir, emtricitabine, and other drugs. The other drugs category includes cabotegravir, lenacapavir, and others. By dosage form, the market is segmented into oral and topical. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD) for the above segments.
| By Drug | |
| Tenofovir | |
| Emtricitabine | |
| Other Drugs |
| By Dosage Form | |
| Oral | |
| Topical |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Prophylactic HIV Drugs Market Size Summary
The prophylactic HIV drug market is poised for steady growth, driven by the high global prevalence of HIV and the increasing demand for preventive medications. The market has shown resilience despite the disruptions caused by the COVID-19 pandemic, which saw some antiretroviral drugs being repurposed for COVID-19 treatment. This shift, while initially impacting the market, has led to a resurgence in diagnostic and manufacturing activities, supporting market stability. The involvement of non-profit organizations and significant investments from pharmaceutical and biotechnology companies in HIV research are further propelling market expansion. Regulatory approvals and product launches, such as Excision's EBT-101, are expected to introduce advanced preventive therapies, enhancing market growth prospects. However, challenges such as lower penetration in underdeveloped markets and potential side effects of the drugs may pose constraints.
The oral drug segment is anticipated to dominate the market, attributed to its pharmacokinetic advantages and high patient compliance. The development of new oral drugs and a robust pipeline of candidates are key factors driving this segment's growth. North America stands out as a significant revenue contributor, supported by a technologically advanced healthcare system and favorable reimbursement policies. The region's market growth is further bolstered by increased government funding for HIV prevention and treatment. The market is characterized by fragmentation, with numerous players like AbbVie, Gilead Sciences, and Merck & Co. Inc. actively participating. Recent FDA approvals, such as Sunlenca and Cabenuva, highlight ongoing advancements in HIV treatment options, reinforcing the market's growth trajectory.
Prophylactic HIV Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 High Prevalence of HIV/AIDS
-
1.2.2 Increasing Government Initiatives
-
1.2.3 Increasing R&D Activities
-
-
1.3 Market Restraints
-
1.3.1 Lower Penetration in Underdeveloped Markets
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Drug
-
2.1.1 Tenofovir
-
2.1.2 Emtricitabine
-
2.1.3 Other Drugs
-
-
2.2 By Dosage Form
-
2.2.1 Oral
-
2.2.2 Topical
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Prophylactic HIV Drugs Market Size FAQs
What is the current Prophylactic HIV Drugs Market size?
The Prophylactic HIV Drugs Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Prophylactic HIV Drugs Market?
Merck & Co., Inc., Cipla Inc, Bristol-Myers Squibb Company, Viatris Inc. (Mylan) and Johnson & Johnson are the major companies operating in the Prophylactic HIV Drugs Market.
